Clinical trials: Methotrexate
Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors
Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)
The Phase II NIAGARA-2 study aims to expand on the data from the Phase III NIAGARA study by investigating perioperative durvalumab in combination with cisplatin based neoadjuvant chemotherapy in a clinical practice setting.
- Conditions
- Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors, Methotrexate, Vinblastine
- Trial name
- NCT06960577
- Testing
- Durvalumab, Methotrexate, Vinblastine
- Where
- 59 sites in Australia, Brazil and 5 more
- Volunteers
- 150 people
- Sponsor
- AstraZeneca
Pharmacokinetics of Isavuconazole, Pharmacokinetics of Methotrexate
A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Methotrexate
The purpose of this study is to assess the effect of multiple doses of isavuconazole on the pharmacokinetics of a single dose of methotrexate.
- Conditions
- Pharmacokinetics of Isavuconazole, Pharmacokinetics of Methotrexate, Pharmacokinetics of 7-hydroxymethotrexate, Healthy Subjects
- Trial name
- NCT01884636
- Testing
- isavuconazole, methotrexate
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Global Development, Inc.